{"preliminary_commentary":{"by_channel":{"x_thread":31,"podcast":8,"youtube":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02924376\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["pemigatinib"]],"indication":"previously treated advanced or metastatic cholangiocarcinoma","name":"FIGHT-202","nct_id":"NCT02924376","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fight-202-nct02924376. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Pemigatinib in subjects with FGFR2 translocation with a documented fusion partner in central laboratory report","label":"Cohort A Pemigatinib","type":"EXPERIMENTAL"},{"description":"Pemigatinibin subjects with other FGF/FGFR alterations","label":"Cohort B Pemigatinib","type":"EXPERIMENTAL"},{"description":"Pemigatinib in subjects negative for FGF/FGFR alteration","label":"Cohort C Pemigatinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2022-02-01","type":"ACTUAL"},"conditions":["Cholangiocarcinoma"],"enrollment":{"count":147,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pemigatinib","otherNames":["INCB054828"],"type":"DRUG"}],"last_update":"2025-08-14","lead_sponsor":"Incyte Corporation","official_title":"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-02-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions","timeFrame":"up to 1527 days"}],"references":[{"citation":"Patel TH, Marcus L, Horiba MN, Donoghue M, Chatterjee S, Mishra-Kalyani PS, Schuck RN, Li Y, Zhang X, Fourie Zirkelbach J, Charlab R, Liu J, Yang Y, Lemery SJ, Pazdur R, Theoret MR, Fashoyin-Aje LA. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement. Clin Cancer Res. 2023 Mar 1;29(5):838-842. doi: 10.1158/1078-0432.CCR-22-2036.","pmid":"36206041","type":"DERIVED"},{"citation":"Bibeau K, Feliz L, Lihou CF, Ren H, Abou-Alfa GK. Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response. JCO Precis Oncol. 2022 Apr;6:e2100414. doi: 10.1200/PO.21.00414.","pmid":"35544727","type":"DERIVED"},{"citation":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Feliz L, Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20.","pmid":"32203698","type":"DERIVED"}],"start_date":{"date":"2017-01-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)","url":"https://clinicaltrials.gov/study/NCT02924376"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fight-202-nct02924376"}